Recent weeks have seen Advanz Pharma make a number of portfolio-diversifying deals, including licensing and supply agreements and product acquisitions. Most notably, the company has acquired exclusive rights to register and commercialize Dimerix’s Phase III drug candidate DMX-200.
Deals Abound At Advanz
Company Has Closed Or Signed Several Agreements Since Early September
Advanz has acquired exclusive rights to register and commercialize a Phase III candidate from Dimerix in multiple territories, alongside agreements with Kyowa Kirin, Bayer and GP Pharm.
More from Deals
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.
• By
Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.
• By
Along with financial backing from the Canadian government, a fresh, decade-long partnership with Sandoz Canada will allow Delpharm to carry out modernization plans for its manufacturing facility in Boucherville, securing the local supply chain for sterile injectable medicines.